Glucocorticoids and rheumatoid arthritis - A reappraisal

Indian Journal of Rheumatology

Volumn 3, Issue 1, 2008, Pages 21-28

  Chaudhuri, Kaushik ^a   Paul, A ^a  

^a UNIVERSITY HOSPITALS COVENTRY AND WARWICKSHIRE NHS TRUST   (United Kingdom)

Author keywords

Glucocorticoids; Rheumatoid arthritis; Steroids

Indexed keywords

A 276575; AL 438; ANTIINFLAMMATORY AGENT; CORTICOSTEROID; CORTISONE; DISEASE MODIFYING ANTIRHEUMATIC DRUG; GLUCOCORTICOID; GLUCOCORTICOID RECEPTOR ALPHA; GLYCYRRHETINIC ACID; INFLIXIMAB; LIPOSOME; METHOTREXATE; METHYLPREDNISOLONE; NCX 1015; NITRIC OXIDE; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; PREDNISOLONE; SALAZOSULFAPYRIDINE; SELECTIVE GLUCOCORTICOID RECEPTOR AGONIST; UNCLASSIFIED DRUG; ZK 2I 6348;

ANTIINFLAMMATORY ACTIVITY; ATHEROSCLEROSIS; BONE NECROSIS; CARDIOVASCULAR DISEASE; CATARACT; CENTRAL NERVOUS SYSTEM DISEASE; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; CUSHINGOID SYNDROME; DRUG DELIVERY SYSTEM; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG INDICATION; DRUG MEGADOSE; DRUG PROTEIN BINDING; DRUG RECEPTOR BINDING; DRUG RESPONSE; DYSLIPIDEMIA; ENDOCRINE DISEASE; ENZYME ACTIVATION; ESTROGEN BLOOD LEVEL; GLAUCOMA; GLUCOSE BLOOD LEVEL; HEART ARRHYTHMIA; HORMONE SYNTHESIS; HUMAN; HYPERGLYCEMIA; HYPERTENSION; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; INFECTION; JUVENILE RHEUMATOID ARTHRITIS; LOW DRUG DOSE; MOOD DISORDER; MUSCLE ATROPHY; MYOPATHY; OSTEOPOROSIS; OUTCOME ASSESSMENT; PANCREATITIS; PEPTIC ULCER; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PSYCHOSIS; REVIEW; RHEUMATOID ARTHRITIS; RISK BENEFIT ANALYSIS; SIDE EFFECT; SKIN DISEASE; TESTOSTERONE BLOOD LEVEL; TREATMENT DURATION; WEIGHT GAIN;

EID: 84992238853     PISSN: 09733698     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0973-3698(10)60075-1     Document Type: Review

References (35)

1. Moreland LW, Russell AS, Paulus HE. Management of Rheumatoid Arthritis, the historical context. J Rheumatol 2001; 28: 1431-52.
2. Copeman WSC. Textbook of Rheumatic Diseases. Chapter 10, 3rd ed. E&S Livingstone, 1964: 175-239.
3. Lightfoot RW, McCarty DJ, editors. Arthritis and Allied Conditions. 10th ed. Baltimore Lea and Febiger, 1985:668.
4. Ward JR. Earlier interventions with second line therapies. J Rheumatol 1990; 17: 18-23.
5. Townsend HB, Sang KG. Glucocorticoid use in rheumatoid arthritis: benefits, mechanisms, and risks. Clin Exp Rheumatol 2004; 22: S77-S82.
6. Neeck G. Fifty years of experience with cortisone therapy in the study of treatment of RA. Ann N Y Acad Sci 2002; 966: 28-38.
7. Joint Committee of the Medical Research Council and the Nuffield Foundation. Clinical trials of cortisone, ACTH and other therapeutic measures in chronic rheumatic diseases. A comparison of prednisolone with aspirin and other analgesics in the treatment of rheumatoid arthritis. Ann Rheum Dis 1960; 19: 331-7.
8. Conn DL. Resolved: low dose prednisone is indicated as standard treatment in patients with rheumatoid arthritis. Arthritis Care Res 2001; 45: 462-7.
9. Kirwan JR. The effect of glucocorticoids on joint destruction in rheumatoid arthritis. The Arthritis Rheumatism Council Low-Dose Glucocorticoid Study Group. New Eng J Med 1995; 333: 142-6.
10. Kirwan J, Power L. Glucocorticoids in rheumatic diseases. Topical reviews. Arthritis Res Campaign 2007; 13: 1-8 (www.arc.org.uk).
11. Buttgereit F, Straub RH, Wehling M, Burmester GR. Glucocorticoids in the treatment of rheumatoid diseases. Arthritis Rheum 2004; 50: 3408-17.
12. Sliwinska-Stanczyk P, Pazdur J, Ziolkowska M, Jaworski J, Kaminska-Tchorzewska E, Lacki JK, et al. The effect of methylprednisolone on proliferation of PBMCs obtained from steroid sensitive and steroid resistant rheumatoid arthritis patients. Scand J Rheumatol 2007; 36: 167-71.
13. Weinblatt ME, Kremer JM, Coblyn JS, Maier AL, Helfgott SM, Morrell M, et al. Pharmacokinetics, safety and efficacy of combination treatment with methotrexate and leflunomide in patients with active rheumatoid arthritis. Arthritis Rheum 1999; 42: 1322-8.
14. Thiele K, Buttgereit F, Huscher D, Zink A. Current use of glucocorticoids in patients with rheumatoid arthritis in Germany. Arthritis Rheum 2005; 53: 740-7.
15. Criswell LA, Sang KG, Sems KM, Welch V, Shea B, Wells G, et al. Moderate term low dose corticosteroids for rheumatoid arthritis. Cochrane Database Syst Rev 1998; 3: Art No. CD001158.
16. Harris ED Jr, Emkey RD, Nichols JE, Newberg A. Low dose prednisolone therapy in rheumatoid arthritis: a double blind study. J Rheumatol 1983; 10: 713-21.
17. van Schaardenberg D, Valkema R, Dijkmans BAC, Papapoulos S. Prednisone treatment of elderly onset rheumatoid arthritis: disease activity and bone mass in comparison to chloroquine treatment. Athritis Rheum 1995; 38: 334-42.
18. van Gestel AM, Laan RF, Haagsma CJ, van de Putte LB, van Riel PL. Low dose oral steroids as bridge therapy in rheumatoid patients starting with parenteral gold. A randomised double blind placebo controlled trial. Br J Rheumatol 1995; 34: 347-51.
19. Boers M, Verhoeven AC, Markusse HM, van de Laar MA, Westhovens R, van Denderen JC, et al. Randomised comparison of combined step down prednisolone, methotrexate and sulphasalazine with sulphasalazine alone in early rheumatoid arthritis. Lancet 1997; 350: 309-18.
20. Hansen M, Podenphant J, Florescu A, Stoltenberg M, Borch A, Kluger E, et al. A randomised trial of differentiated prednisolone treatment in active rheumatoid arthritis: clinical benefits and skeletal side effects. Ann Rheum Dis 1999; 58: 713-8.
21. Kirwan J, Byron M, Watt I. Relationship between soft tissue swelling, joint space narrowing and erosive damage in hand X-rays of patients with rheumatoid arthritis. Rheumatology 2001; 40: 297-301.
22. van Everdingen AA, Jacobs JWG, van Reesema DRS, Bijlsma JWJ. Low dose prednisolone therapy for patients with early active rheumatoid arthritis: clinical efficacy, disease modifying properties and side effects. A randomised, double blind placebo controlled trial. Ann Int Med 2002; 136: 1-12.
23. Capell HA, Madhok R, Hunter JA, Porter D, Morrison E, Larkin J, et al. Lack of radiological and clinical benefit over two years of low dose prednisolone for rheumatoid arthritis: results of a randomised controlled trial, Ann Rheum Dis 2004; 63: 797-803.
24. Suponitskaia EV, Smirnov AV, Aleksandrova EN, Novikov AA, Nasonov EL. Effects of small dose glucocorticoids on the course of early rheumatic arthritis. Klin Med 2004; 82: 39-42.
25. Choy EH, Kingsley GH, Khoshaba B, Pipitone N, Scott DL. A two year controlled trial of intramuscular depot steroids in patients with established rheumatoid arthritis who have shown an incomplete response to disease modifying anti-rheumatic drugs. Ann Rheum Dis 2005; 64: 1288-93.
26. Goekoop-Ruiterman YP, de Vries-Bouwstra JK, Allaart CF, van Zeben D, Kerstens PJ, Hazes JM, et al. Clinical and radiographic outcomes of four different treatment strategiesin patients with early rheumatoid arthritis (the BeST) study: a randomised controlled trial. Arthritis Rheum 2005; 52: 3381-90.
27. Svensson B, Boonen A, Albertsson K, van der Heijde D, Keller C, Hafström I for the BARFOT study group. Low dose prednisolone in addition to the initial disease modifying anti rheumatic drug in patients with active rheumatoid arthritis-reduces joint destruction and reduces remission rate - a two year randomised trial. Arthritis Rheum 2005; 52: 3360-70.
28. Wassenberg S, Rau R, Steinfeld P, Zeidler H. Very low dose prednisolone in early rheumatoid arthritis retards radiographic progression over two years. A multi centre double blind placebo controlled trial. Arthritis Rheum 2005: 3371-80.
29. Kirwan JR, Bijlsma JW, Boers M, Shea BJ. Effects of glucocorticoids on the radiological progression. in rheumatoid arthritis. Cochrane Database Syst Rev 2007; 1: CD 006356.
30. Landewé RB, Boers M, Verhoeven AC, Westhovens R, van de Laar MA, Markusse HM. COBRA combination therapy in patients with early rheumatoid arthritis. Long-term structural benefits of a brief intervention. Arthritis Rheum 2002; 46: 347-56.
31. Jacobs JWG, van Everindingen AA, Verstappen SMM, Bijlsma JWJ. Follow-up radiological data on patients with rheumatoid arthritis who participated in a two year trial of prednisolone therapy or placebo. Arthritis Rheum 2006; 54: 1422-28.
32. Da Silva JA, Jacobs JWG, Bijlsma JWJ. Revisiting the toxicity of low dose glucocorticoids. Ann N Y Acad Sci 2006; 1069: 275-88.
33. Dekkers JC, Geenen R, Godaert GL, van Doornen LJ, Bijlsma JWJ. Diurnal rhythm of salivary cortisol in patients with rheumatoid arthritis of recent onset. Arthritis Rheum 2000; 43: 465-6.
34. Hansen M, Pødenphant J, Florescu A, Stoltenberg M, Borch A, Kluger E, et al. A randomised trial of differentiated prednisolone treatment in active rheumatoid arthritis: clinical benefits and skeletal side effects. Ann Rheum Dis 1999; 58: 713-18.
35. Bijlsma JWJ, Buttergeit F, Jacobs JWG. Systemic and intra - articular glucocorticoids in rheumatoid arthritis in rheumatoid arthritis. In: Firestein G, Panayi G, Wollheim FA, editors. 2nd revised ed. Oxford University Press, 2006: 337-53.